Allogeneic stem cell transplantation for AML patients with RUNX1 mutation in first complete remission: a study on behalf of the acute leukemia working party of the EBMT

被引：0

作者：

Johanna Waidhauser

Myriam Labopin

Jordi Esteve

Nicolaus Kröger

Jan Cornelissen

Tobias Gedde-Dahl

Gwendolyn Van Gorkom

Jürgen Finke

Montserrat Rovira

Nicolaas Schaap

Eefke Petersen

Dietrich Beelen

Donald Bunjes

Bipin Savani

Christoph Schmid

Arnon Nagler

Mohamad Mohty

机构：

[1] Department of Hematology and Medical Oncology,Institute of Hematology and Oncology

[2] University Medical Center Augsburg,undefined

[3] EBMT Paris Study Office,undefined

[4] Saint Antoine Hospital,undefined

[5] INSERM UMR 938,undefined

[6] Sorbonne University,undefined

[7] Hospital Clinic Barcelona,undefined

[8] Bone Marrow Transplantation Centre,undefined

[9] University Hospital Eppendorf,undefined

[10] Department of Hematology,undefined

[11] University Medical Center Rotterdam,undefined

[12] Clinic for Cancer Medicine,undefined

[13] Oslo University Hospital,undefined

[14] Rikshospitalet,undefined

[15] Department of Internal Med. Hematology /Oncology,undefined

[16] University Hospital Maastricht,undefined

[17] Department of Hematology and Medical Oncology,undefined

[18] University of Freiburg,undefined

[19] Department of Hematology,undefined

[20] Nijmegen Medical Centre,undefined

[21] Department of Hematology,undefined

[22] University Medical Centre Utrecht,undefined

[23] Department of Bone Marrow Transplantation,undefined

[24] University Hospital Essen,undefined

[25] Klinik fuer Innere Medizin III,undefined

[26] University Hospital Ulm,undefined

[27] Vanderbilt University Medical Center,undefined

[28] Tel Aviv University,undefined

[29] BMT and Cord Blood Bank,undefined

[30] Chaim Sheba Medical Center,undefined

[31] Department of Hematology,undefined

[32] Saint Antoine Hospital,undefined

来源：

Bone Marrow Transplantation | 2021年 / 56卷

关键词：

D O I：

暂无

中图分类号：

学科分类号：

摘要：

Acute myeloid leukemia with runt-related transcription factor 1 gene mutation (RUNX1+ AML) is associated with inferior response rates and outcome after conventional chemotherapy. We performed a retrospective, registry-based analysis to elucidate the prognostic value of RUNX1 mutation after allogeneic stem cell transplantation (alloSCT). All consecutive adults undergoing alloSCT for AML in first complete remission (CR1) between 2013 and 2019 with complete information on conventional cytogenetics and RUNX1 mutational status were included. Endpoints of interest were cumulative relapse incidence, non-relapse mortality, overall and leukemia-free survival (OS/LFS), and GvHD-free/relapse-free survival. A total of 674 patients (183 RUNX1+, 491 RUNX1−) were identified, with >85% presenting as de novo AML. Median follow-up was 16.4 (RUNX1+) and 21.9 (RUNX1−) months. Survival rates showed no difference between RUNX1+ and RUNX1− patients either in univariate or multivariate analysis (2-year OS: 67.7 vs. 66.1%, p = 0.7; 2-year LFS: 61.1 vs. 60.8%, p = 0.62). Multivariate analysis identified age, donor type and poor cytogenetics as risk factors for inferior outcome. Among patients with RUNX+ AML, older age, reduced intensity conditioning and minimal residual disease at alloSCT predicted inferior outcome. Our data provide evidence that the negative influence of RUNX1 mutations in patients with AML can be overcome by transplantation in CR1.

引用

页码：2445 / 2453

页数：8

共 162 条

[1]

Arber DA(2016)The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia Blood 127 2391-405

[2]

Orazi A(2017)Molecular biomarkers in acute myeloid leukemia Blood Rev 31 63-76

[3]

Hasserjian R(2009)AML1/RUNX1 mutations in 470 adult patients with de novo acute myeloid leukemia: prognostic implication and interaction with other gene alterations Blood 114 5352-61

[4]

Thiele J(2011)RUNX1 mutations are frequent in de novo AML with noncomplex karyotype and confer an unfavorable prognosis Blood 117 2348-57

[5]

Borowitz MJ(2011)RUNX1 mutations in acute myeloid leukemia: results from a comprehensive genetic and clinical analysis from the AML study group J Clin Oncol : Off J Am Soc Clin Oncol 29 1364-72

[6]

Le Beau MM(2012)RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression signatures J Clin Oncol : Off J Am Soc Clin Oncol 30 3109-18

[7]

Prada-Arismendy J(2016)RUNX1 mutations in acute myeloid leukemia are associated with distinct clinico-pathologic and genetic features Leukemia 30 2160-8

[8]

Arroyave JC(2012)RUNX1 mutations in cytogenetically normal acute myeloid leukemia are associated with a poor prognosis and up-regulation of lymphoid genes Haematologica 97 1909-15

[9]

Rothlisberger S(2017)Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel Blood 129 424-47

[10]

Tang JL(1998)The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children’s Leukaemia Working Parties Blood 92 2322-33

← 1 2 3 4 5 6 7 8 9 10 →